| Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. | None |
| The proto-oncogene c-myc is involved in cell differentiation as well as cell proliferation: studies on growth plate chondrocytes in situ. | None |
| Oncogenic remodeling of the three-dimensional organization of the interphase nucleus: c-Myc induces telomeric aggregates whose formation precedes chromosomal rearrangements. | None |
| A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. | None |
| Mechanism of estrogen activation of c-myc oncogene expression. | None |
| Development of multidrug resistance due to multiple factors including P-glycoprotein overexpression under K-selection after MYC and HRAS oncogene activation. | None |
| Genetic heterogeneity of the MYC oncogene in advanced juvenile angiofibromas. | None |
| PEG10 is a direct target of c-MYC; findings link cancer genetics and epigenetics by showing that a classic proto-oncogene, MYC, acts directly upstream of a proliferation-positive imprinted gene, PEG10 | None |
| Molecular cloning of the avian acute transforming retrovirus MH2 reveals a novel cell-derived sequence (v-mil) in addition to the myc oncogene. | None |
| Integration of papillomavirus DNA near myc genes in genital carcinomas and its consequences for proto-oncogene expression. | None |
| Doubling the hMYC level by breeding homozygous transgenic animals switched the phenotype from primarily monocytic tumors to exclusively T-cell tumors. Results imply that MYC level affects the spontaneous acquisition of synergistic oncogenic mutations. | None |
| Transcriptional activation by the Myc oncoprotein. | None |
| The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. | None |
| EGF promotes in vivo tumorigenic growth of primary chicken embryo fibroblasts expressing v-myc and enhances in vitro transformation by the v-erbA oncogene. | None |
| Myc influences global chromatin structure. | None |
| Effects of IL-3 on promoter usage, attenuation and antisense transcription of the c-myc oncogene in the IL-3-dependent Ba/F3 early pre-B cell line. | None |
| Differing lesions cooperate oncogenically with Myc by discrete mechanisms that can themselves synergize with each other. | None |
| Data suggest that c-MYC and Wnt1 select for the outgrowth of cells with mutations in specific ras isoforms such as Kras2, and that these mutations determine the extent of ras/MAPK pathway activation and the potential for oncogene-independent growth. | None |
| The Myc oncoprotein as a therapeutic target for human cancer. | None |
| Noncorrelative c-myc and ras oncogene expression in squamous cell carcinoma cells with tumorigenic potential. | None |